What is Accent Therapeutics?
Accent Therapeutics is a biopharmaceutical company dedicated to developing novel small molecule therapeutics for cancer. Leveraging its deep expertise in RNA-modifying protein biology, the company targets critical intracellular dependencies to address significant unmet medical needs in large patient populations. Their strategic approach focuses on creating both first-in-class and best-in-class treatments, aiming to make a substantial impact on cancer care.
How much funding has Accent Therapeutics raised?
Accent Therapeutics has raised a total of $178M across 3 funding rounds:
Series A
$40M
Series B
$63M
Series C
$75M
Series A (2018): $40M, investors not publicly disclosed
Series B (2020): $63M led by AbbVie Biotech Ventures , Inc., The Column Group, NS Investment, The Mark Foundation for Cancer Research, Droia Ventures, Google Ventures, Atlas Venture, and EcoR1 Capital LLC
Series C (2024): $75M supported by Johnson & Johnson Innovation, The Column Group, Bristol-Myers Squibb, and Mirae Asset Financial Group
Key Investors in Accent Therapeutics
Johnson & Johnson Innovation
Johnson & Johnson Innovation is a pharmaceutical manufacturing company focused on positively impacting human health through innovation, partnering with early-stage businesses to develop global healthcare solutions.
The Column Group
The Column Group is a venture ecosystem dedicated to advancing scientific innovation in the life sciences sector, supporting the formation and growth of biotechnology companies through its investment model.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical organization focused on discovering, developing, and manufacturing prescription medications for serious patient needs across oncology, cardiovascular disease, and other therapeutic domains.
What's next for Accent Therapeutics?
The recent major enterprise-level funding and strategic investment signal Accent Therapeutics' readiness to accelerate its development pipeline and potentially expand its research and development efforts. This capital infusion is expected to fuel the progression of its therapeutic programs through clinical trials and towards market approval. The company's focus on RNA-modifying protein biology positions it at the forefront of innovative cancer treatment strategies, suggesting a future trajectory aimed at delivering life-changing therapies.
See full Accent Therapeutics company page
